4D pharma files Registration Statement on Form F-4 with U.S. Securities and Exchange Commission
4d Pharma PLC (DDDD.L) Registration Statement filed with SEC
4d Pharma PLC (DDDD.L) Longevity extends Business Combination deadline
Longevity receives shareholder approval to extend business combination deadline
4d Pharma PLC (DDDD.L) Presentations on MRx0518 at SITC 2020
4D pharma announces three presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020
4d Pharma PLC (DDDD.L) Topline Results for Blautix® phase II trial
Positive trends seen in primary efficacy endpoint of the study of overall response in both IBS-C and IBS-D subgroups
4d Pharma PLC (DDDD.L) Interim Results
Interim results for the six months ended 30 June 2020
4d Pharma PLC (DDDD.L) MRx0158 Keytruda Part A clinical benefit data
4D pharma announces comprehensive clinical benefit data from Part A of combination trial of MRx0518 and Keytruda®
Evgen Pharma PLC (EVG.L) SFX-01 to be evaluated in COVID-19 trial
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company, is delighted to announce participation in the recently notified funding initiative for COVID-19 clinical trials by the medical research
Evgen Pharma (EVG.L) Clinical trial that could reduce Covid-19 deaths
The University of Dundee is leading the clinical trial of a new anti-inflammatory drug it is hoped may reduce instances of severe lung damage and death in Covid-19 patients.
Integumen PLC (LON:SKIN) CEO Gerry Brandon ‘ move into clinical trials.
Integumen PLC (LON:SKIN) CEO Gerry Brandon speaks to Proactive London’s Andrew Scott soon after announcing the roll-out of a new Labskin test designed to clone the skin of volunteers in clinical
